Amicus Therapeutics Inc
$ 14.33
-0.07%
04 Mar - close price
- Market Cap 4,499,630,000 USD
- Current Price $ 14.33
- High / Low $ 14.36 / 14.33
- Stock P/E N/A
- Book Value 0.88
- EPS -0.09
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE -0.12 %
- 52 Week High 14.38
- 52 Week Low 5.51
About
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing and delivering drugs for people living with rare metabolic diseases. The company is headquartered in Philadelphia, Pennsylvania.
Analyst Target Price
$14.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-04 | 2025-07-31 | 2025-05-07 | 2025-02-26 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-08 | 2023-08-08 | 2023-05-10 |
| Reported EPS | 0.1 | 0.06 | -0.08 | 0.03 | 0.09 | -0.02 | -0.05 | -0.16 | -0.11 | -0.07 | -0.15 | -0.18 |
| Estimated EPS | 0.065 | 0.03 | -0.11 | -0.07 | 0.0911 | -0.01 | -0.06 | -0.07 | -0.06 | -0.08 | -0.12 | -0.15 |
| Surprise | 0.035 | 0.03 | 0.03 | 0.1 | -0.0011 | -0.01 | 0.01 | -0.09 | -0.05 | 0.01 | -0.03 | -0.03 |
| Surprise Percentage | 53.8462% | 100% | 27.2727% | 142.8571% | -1.2075% | -100% | 16.6667% | -128.5714% | -83.3333% | 12.5% | -25% | -20% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.028 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FOLD
2026-03-04 10:52:54
JPMorgan Chase & Co. reduced its stake in Amicus Therapeutics (NASDAQ:FOLD) by 4.3% in the third quarter, holding 2.12 million shares valued at $16.68 million. Several other hedge funds also adjusted their positions in the biopharmaceutical company during the quarter. Amicus Therapeutics stock opened at $14.34, with recent earnings missing analyst estimates, while analysts currently hold a consensus "Hold" rating and a price target of $15.39.
2026-03-04 08:52:54
This article analyzes Amicus Therapeutics (FOLD) after its proposed BioMarin deal price of US$14.50. It uses discounted cash flow (DCF) and price-to-sales (P/S) analyses, both suggesting the stock is undervalued, with the DCF model indicating a 76.5% undervaluation compared to its current price of US$14.34. The article also presents "Narratives" for investors to weigh bullish and bearish cases, factoring in the potential acquisition and risks like product concentration.
2026-03-03 20:52:54
Amicus Therapeutics shareholders have approved the company's acquisition by BioMarin Pharmaceutical, satisfying a major condition for the merger. The merger proposal passed with overwhelming support, and an advisory vote on executive compensation also received approval. While the U.S. Federal Trade Commission granted early termination of the Hart-Scott-Rodino waiting period, the transaction, expected to close in Q2 2026, still requires regulatory clearances from certain non-U.S. jurisdictions.
2026-03-02 12:51:30
Vanguard Group Inc. increased its stake in Amicus Therapeutics (NASDAQ:FOLD) by 0.4% in the third quarter, acquiring an additional 126,441 shares, bringing its total holding to over 29.5 million shares valued at approximately $232.7 million. Analyst ratings for Amicus Therapeutics are mixed, with a consensus "Hold" rating and a $15.39 target price, while insiders have been net sellers, including CEO Bradley L. Campbell. The company reported $185.21 million in revenue and $0.10 EPS for its latest quarter, missing consensus EPS estimates.
2026-03-01 13:52:19
William Blair Investment Management LLC significantly increased its stake in Amicus Therapeutics, purchasing over 1.1 million shares to own 5.10% of the company. Despite mixed analyst sentiment with an average "Hold" rating, several other institutional investors also adjusted their positions in FOLD. The company recently reported Q4 earnings, missing EPS estimates but showing a 23.7% year-over-year revenue increase, while insiders sold a notable amount of stock.
2026-03-01 10:52:19
Fox Run Management L.L.C. has acquired a new position in Amicus Therapeutics, purchasing 70,115 shares valued at approximately $553,000 in the third quarter. While institutional investors like Vanguard and Vestal Point Capital have increased their stakes, analysts largely maintain a "Hold" rating on the stock with an average price target of $15.39. Amicus Therapeutics recently missed EPS estimates but showed strong revenue growth, though insider selling by the CEO and other executives has also been noted.
